Pertuzumab

Aug 29, 2017

Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer

Aug 29, 2017

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer

Aug 17, 2017

HER2 Antibodies Market to Reach US$ 21,669.1 Million by 2025; Perjeta and Other Promising Pipeline Drugs Augur well for Future

Jun 05, 2017

New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting